Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
While novel kinase inhibitor (KI) medications such as ibrutinib and idelalisib have revolutionized care for chronic lymphocytic leukemia (CLL), some patients just can’t tolerate them and that is a common reason they need to stop therapy. Finding options for such patients is a significant unmet need in CLL. This is a phase 2 open label trial of an experimental drug, TGR-1202 which is a different KI that may be better tolerated. The trial is to study that question and to assess progression free survival. It is open to those who needed to stop ibrutinib, acalabrutinib, duvelisib, idelalisib or other KIs due to adverse side effects within the last year. It is not for those patients whose CLL progressed on those drugs.
The poster gives more details. You can view it here.
Here is a link to the trial: https://clinicaltrials.gov/ct2/show/NCT02742090?term=TGR-1202&recrs=a&cond=CLL&cntry1=NA%3AUS&rank=3
Disclaimer: Please carefully review this or any clinical trial or therapy decision with your treatment team. The CLL Society wants you to be informed of all your treatment options but does not endorse any particular trial or therapy, including this one.
7/11/17
Related posts